Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oligodeoxynucleotide analogs with 5'-linked anthraquinone.

K Mori1, C Subasinghe, J S Cohen

  • 1Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892.

FEBS Letters
|June 5, 1989
PubMed
Summary

Researchers synthesized novel 5'-linked oligodeoxynucleotides with attached anthraquinone. These compounds deliver reactive drug-like molecules to target nucleic acids, forming a new class of antisense agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The incremental risk of fragility fractures in aging men.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

De novo variants in KLF7 are a potential novel cause of developmental delay/intellectual disability, neuromuscular and psychiatric symptoms.

Clinical genetics·2017
Same author

Expansion and further delineation of the SETD5 phenotype leading to global developmental delay, variable dysmorphic features, and reduced penetrance.

Clinical genetics·2017
Same author

Further evidence that de novo missense and truncating variants in ZBTB18 cause intellectual disability with variable features.

Clinical genetics·2016
Same author

Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life.

Clinical genetics·2014
Same author

The role of trial tracking on rats' successive delayed matching-to-sample modality performance.

Behavioural processes·2014

Area of Science:

  • Medicinal Chemistry
  • Oligonucleotide Synthesis
  • Antisense Technology

Background:

  • Antisense technology utilizes short DNA or RNA sequences to target specific nucleic acids.
  • Developing stable and effective delivery systems for antisense compounds is crucial.
  • Anthraquinones are known for their reactivity and potential therapeutic applications.

Purpose of the Study:

  • To synthesize novel 5"-linked oligodeoxynucleotides modified with anthraquinone.
  • To explore a new class of antisense compounds with enhanced drug-like properties.
  • To investigate the potential of these compounds for targeted nucleic acid delivery.

Main Methods:

  • Synthesis of normal phosphodiester and phosphorothioate oligodeoxynucleotides.
  • Covalent attachment of an anthraquinone group at the 5 -terminus.

Related Experiment Videos

  • Characterization of the synthesized novel compounds.

    • Main Results:

    • Successful synthesis of novel 5 -linked oligodeoxynucleotides containing anthraquinone.
    • Demonstration of these compounds as a new class of antisense agents.
    • The base sequence directs the delivery of a nuclease-resistant, reactive molecule.

    Conclusions:

    • The synthesized compounds offer a novel approach to antisense therapy.
    • The anthraquinone moiety enhances the drug-like characteristics and stability.
    • These novel oligodeoxynucleotides show promise for targeted delivery to cellular nucleic acids.